Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Amicus Therapeutics (FOLD)

Amicus Therapeutics (FOLD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Amicus Therapeutics 47 Hulfish Street Princeton NJ 08542 USA

www.amicusrx.com Employees: 499 P: 609-662-2000 F: 609-662-2001

Sector:

Medical

Description:

Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.'The company has one marketed medicine in its portfolio named Galafold which is the first and the only approved oral precision medicine for patients living with Fabry disease, having amenable genetic variants. Migalastat is a potent orally available inhibitor of alpha-Gal A.'The drug was granted an accelerated approval by the FDA for treating adult patients with a confirmed diagnosis of Fabry disease and an amenable genetic variant. Galafold is the first and only oral therapy approved in the EU for the long-term treatment of adolescents with Fabry disease.'The lead pipeline candidate in the company's portfolio is AT-GAA, a differentiated biologic for Pompe disease. The company has one gene-therapy program in its pipeline CLN3, a type of Batten disease, being evaluated in a phase I/II study.

Key Statistics

Overview:

Market Capitalization, $K 4,415,122
Enterprise Value, $K 4,591,482
Shares Outstanding, K 308,534
Float, K 301,746
% Float 97.80%
Short Interest, K 19,056
Short Float 6.18%
Days to Cover 1.00
Short Volume Ratio 0.32
% of Insider Shareholders 2.20%

Financials:

Annual Sales, $ 528,300 K
Annual Net Income, $ -56,110 K
Last Quarter Sales, $ 169,060 K
Last Quarter Net Income, $ 17,310 K
EBIT, $ 40,420 K
EBITDA, $ 51,230 K

Growth:

1-Year Return 50.89%
3-Year Return 11.54%
5-Year Return -24.33%
5-Year Revenue Growth 189.89%
5-Year Earnings Growth 96.95%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.17 on 11/04/25
Next Earnings Date 02/18/26
Earnings Per Share ttm 0.04
EPS Growth vs. Prev Qtr 320.00%
EPS Growth vs. Prev Year 175.00%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

FOLD Ratios

Ratio
Price/Earnings ttm 358.25
Price/Earnings forward 34.67
Price/Earnings to Growth N/A
Return-on-Equity % 6.95%
Return-on-Assets % 1.75%
Profit Margin % -10.62%
Debt/Equity 1.70
Price/Sales 7.36
Price/Cash Flow N/A
Price/Book 19.19
Book Value/Share 0.75
Interest Coverage -0.42
60-Month Beta 0.42
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar